Telavancin (VIBATIV) for the treatment of complicated skin and skin structure infections

References

• Ki V, Rotstein C. Bacterial skin and soft tissue infections in adults: A review of their epidemiology, pathogenesis, diagnosis, treatment and site of care. Can J Infect Dis Med Microbiol 2008;19(2):173-84
   PubMed Web of Science ®Google Scholar
• Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006;355(7):666-74
   PubMed Web of Science ®Google Scholar
• Zervos MJ, Freeman K, Vo L, et al. Epidemiology and outcomes of complicated skin and soft tissue infections in hospitalized patients. J Clin Microbiol 2012;50(2):238-45
   PubMed Web of Science ®Google Scholar
• Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis 2014;59(2):147-59
   PubMed Web of Science ®Google Scholar
• Griffith RS. Introduction to vancomycin. Rev Infect Dis 1981;3 suppl:S200-4
   Google Scholar
• Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006;42(Suppl 1):S35-9
   PubMedGoogle Scholar
• Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother 2007;60(4):788-94
   PubMed Web of Science ®Google Scholar
• Wang G, Hindler JF, Ward KW, Bruckner DA. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 2006;44(11):3883-6
   PubMed Web of Science ®Google Scholar
• Rubinstein E, Keynan Y. Vancomycin revisited - 60 years later. Front Public Health 2014;2:217
   PubMedGoogle Scholar
• Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006;166(19):2138-44
   PubMedGoogle Scholar
• Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008;46(2):193-200
   PubMed Web of Science ®Google Scholar
• Clinical breakpoints (Bacterial v3.1 and Fungal v6.1). The European Committee on Antimicrobial Susceptibility Testing. Available from: www.eucast.org/clinical_breakpoints Published February 11, 2013 [Accessed 4 October 2013]
   Google Scholar
• CLSI. Performance standards for antimicro- bial susceptibility testing. CLSI approved stan- dard M100-S16. Wayne, PA: CLSI, 2006
   Google Scholar
• Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008;52(4):1330-6
   PubMed Web of Science ®Google Scholar
• Labreche MJ, Lee GC, Attridge RT, et al. Treatment failure and costs in patients with methicillin-resistant Staphylococcus aureus (MRSA) skin and soft tissue infections: a South Texas Ambulatory Research Network (STARNet) study. J Am Board Fam Med 2013;26(5):508-17
   PubMed Web of Science ®Google Scholar
• Mishra NN, Bayer AS, Weidenmaier C, et al. Phenotypic and genotypic characterization of daptomycin-resistant methicillin-resistant Staphylococcus aureus strains: relative roles of mprF and dlt operons. PLoS One 2014;9(9):e107426
   Google Scholar
• Natsumoto B, Yokota K, Omata F, Furukawa K. Risk factors for linezolid-associated thrombocytopenia in adult patients. Infection 2014;42(6):1007-12
   PubMed Web of Science ®Google Scholar
• Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis 2010;50(12):1568-74
   PubMed Web of Science ®Google Scholar
• Leadbetter MR, Adams SM, Bazzini B, et al. Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424). J Antibiot (Tokyo) 2004;57(5):326-36
   Google Scholar
• Saravolatz LD, Pawlak J, Johnson LB. In vitro susceptibilities and molecular analysis of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus isolates. Clin Infect Dis 2012;55(4):582-6
   PubMed Web of Science ®Google Scholar
• Higgins DL, Chang R, Debabov DV, et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005;49(3):1127-34
   PubMed Web of Science ®Google Scholar
• Nannini EC, Stryjewski ME, Corey GR. Telavancin’s interactions with the bacterial cell membrane. Future Microbiol 2010;5(3):355-8
   Google Scholar
• Song Y, Lunde CS, Benton BM, Wilkinson BJ. Further insights into the mode of action of the lipoglycopeptide telavancin through global gene expression studies. Antimicrob Agents Chemother 2012;56(6):3157-64
   Google Scholar
• Pace JL, Krause K, Johnston D, et al. In vitro activity of TD-6424 against Staphylococcus aureus. Antimicrob Agents Chemother 2003;47(11):3602-4
   PubMedGoogle Scholar
• Mendes RE, Sader HS, Flamm RK, et al. Telavancin in vitro activity against a USA collection of methicillin-resistant Staphylococcus aureus, including resistant subsets. Antimicrob Agents Chemother 2015;59(3):1811-14
   PubMed Web of Science ®Google Scholar
• Mendes RE, Sader HS, Farrell DJ, Jones RN. Update on the telavancin activity tested against European staphylococcal clinical isolates (2009-2010). Diagn Microbiol Infect Dis 2011;71(1):93-7
   PubMedGoogle Scholar
• Leonard SN, Szeto YG, Zolotarev M, Grigoryan IV. Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA). Int J Antimicrob Agents 2011;37(6):558-61
   PubMedGoogle Scholar
• Mendes RE, Farrell DJ, Sader HS, et al. Baseline activity of telavancin against Gram-positive clinical isolates responsible for documented infections in U.S. Hospitals (2011-2012) as determined by the revised susceptibility testing method. Antimicrob Agents Chemother 2015;59(1):702-6
   Google Scholar
• Shaw JP, Seroogy J, Kaniga K, et al. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother 2005;49(1):195-201
   PubMed Web of Science ®Google Scholar
• Reyes N, Skinner R, Kaniga K, et al. Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005;49(10):4344-6
   PubMed Web of Science ®Google Scholar
• Nannini EC, Stryjewski ME. A new lipoglycopeptide: telavancin. Expert Opin Pharmacother 2008;9(12):2197-207
   PubMed Web of Science ®Google Scholar
• Kosowska-Shick K, Clark C, Pankuch GA, et al. Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies. Antimicrob Agents Chemother 2009;53(10):4217-24
   PubMedGoogle Scholar
• Sun HK, Duchin K, Nightingale CH, et al. Tissue penetration of telavancin after intravenous administration in healthy subjects. Antimicrob Agents Chemother 2006;50(2):788-90
   Google Scholar
• Lodise TP, Butterfield JM, Hegde SS, et al. Telavancin pharmacokinetics and pharmacodynamics in patients with complicated skin and skin structure infections and various degrees of renal function. Antimicrob Agents Chemother 2012;56(4):2062-6
   PubMed Web of Science ®Google Scholar
• Shaw JP, Cheong J, Goldberg MR, Kitt MM. Mass balance and pharmacokinetics of [14C]telavancin following intravenous administration to healthy male volunteers. Antimicrob Agents Chemother 2010;54(8):3365-71
   PubMed Web of Science ®Google Scholar
• Samara E, Shaw JP, Barriere SL, et al. Population pharmacokinetics of telavancin in healthy subjects and patients with infections. Antimicrob Agents Chemother 2012;56(4):2067-73
   PubMed Web of Science ®Google Scholar
• Barriere SL, Farrell DJ, Rhomberg PR, Jones RN. Serum inhibitory and bactericidal activity of telavancin in non-infected subjects with severe renal impairment or end-stage renal disease. Diagn Microbiol Infect Dis 2014;80(4):327-9
   Google Scholar
• Goldberg MR, Wong SL, Shaw JP, et al. Lack of effect of moderate hepatic impairment on the pharmacokinetics of telavancin. Pharmacotherapy 2010;30(1):35-42
   PubMedGoogle Scholar
• Goldberg MR, Wong SL, Shaw JP, et al. Single-dose pharmacokinetics and tolerability of telavancin in elderly men and women. Pharmacotherapy 2010;30(8):806-11
   Google Scholar
• Wong SL, Goldberg MR, Ballow CH, et al. Effect of Telavancin on the pharmacokinetics of the cytochrome P450 3A probe substrate midazolam: a randomized, double-blind, crossover study in healthy subjects. Pharmacotherapy 2010;30(2):136-43
   Google Scholar
• Stryjewski ME, O’Riordan WD, Lau WK, et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis 2005;40(11):1601-7
   Google Scholar
• Stryjewski ME, Chu VH, O’Riordan WD, et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother 2006;50(3):862-7
   PubMedGoogle Scholar
• Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 2008;46(11):1683-93
   PubMed Web of Science ®Google Scholar
• Rubinstein E, Lalani T, Corey GR, et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis 2011;52(1):31-40
   PubMed Web of Science ®Google Scholar
• Corey GR RE, Stryjewski ME, Bassetti M, Barriere SL. Potential Role for Telavancin in Bacteremic Infections Due to Gram-Positive Pathogens: Focus on Staphylococcus aureus. Clin Infect Dis 2014;60(5):787-96
   Google Scholar
• Marcos LA, Camins BC, Ritchie DJ, et al. Acute renal insufficiency during telavancin therapy in clinical practice. J Antimicrob Chemother 2012;67(3):723-6
   Google Scholar
• Polyzos KA, Mavros MN, Vardakas KZ, et al. Efficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis. PLoS ONE 2012;7(8):e41870
   PubMed Web of Science ®Google Scholar
• Briefing Document for the Anti-Infective Drugs Advisory Committee. Telavancin for the Treatment of Nosocomial Pneumonia. South San Francisco, CA: Theravance, Inc
   Google Scholar
• Rubinstein E, Corey GR, Stryjewski ME, Kanafani ZA. Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia. Expert Opin Pharmacother 2011;12(17):2737-50
   Web of Science ®Google Scholar
• Steven Barriere P, FIDSA, FCCP. Increased risk of mortality in patients with pre-existing renal impairment, risk of nephrotoxicity and risk of fetal development toxicity with VIBATIV (telavancin). June 2013
   Google Scholar
• Vibativ Summary of product characteristics. Clinigen Healthcare Ltd Pitcairn House, Crown Square, First Avenue, Burton-on-Trent United Kingdom; 2011
   Google Scholar
• Barriere SL. The ATTAIN trials: efficacy and safety of telavancin compared with vancomycin for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia. Future Microbiol 2014;9(3):281-9
   PubMed Web of Science ®Google Scholar
• Stryjewski ME, Lentnek A, O’Riordan W, et al. A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study. BMC Infect Dis 2014;14:289
   PubMed Web of Science ®Google Scholar
• A phase 2 telavancin Staphylococcus aureus bacteremia trial. Available from: https://clinicaltrials.gov/ct2/show/NCT02208063
   Google Scholar
• Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 2003;47(4):1318-23
   PubMed Web of Science ®Google Scholar
• Rybak JM, Roberts K. Tedizolid Phosphate: a Next-Generation Oxazolidinone. Infect Dis Ther 2015. [Epub ahead of print]
   Google Scholar
• Kanafani ZA, Corey GR. Tedizolid (TR-701): a new oxazolidinone with enhanced potency. Expert Opin Investig Drugs 2012;21(4):515-22
   PubMed Web of Science ®Google Scholar
• Batts DH. Linezolid–a new option for treating gram-positive infections. Oncology (Williston Park) 2000;14(8 Suppl 6):23-9
   Google Scholar
• Kmeid J, Kanafani ZA. Oritavancin for the treatment of acute bacterial skin and skin structure infections: an evidence-based review. Core Evid 2015;10:39-47
   PubMedGoogle Scholar
• Kanafani ZA. Ceftaroline fosamil: drug profile and clinical data. Future Microbiol 2011;6(1):9-18
   Google Scholar
• Kanafani ZA. Telavancin: a new lipoglycopeptide with multiple mechanisms of action. Expert Rev Anti Infect Ther 2006;4(5):743-9
   PubMedGoogle Scholar
• Krause KM, Barriere SL, Kitt MM, Benton BM. In vitro activity of telavancin against Gram-positive isolates from complicated skin and skin structure infections: results from 2 phase 3 (ATLAS) clinical studies. Diagn Microbiol Infect Dis 2010;68(2):181-5
   PubMedGoogle Scholar